File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A systematic N-terminal peptide quantitative labeling strategy for differential proteomic analysis

TitleA systematic N-terminal peptide quantitative labeling strategy for differential proteomic analysis
Authors
KeywordsCerebrospinal fluid
Guanidination
LTQ-FT MS
MS-based acetyl quantification
N-terminal acetyl labeling
Issue Date2010
Citation
Proteomics - Clinical Applications, 2010, v. 4, n. 6-7, p. 633-643 How to Cite?
AbstractPurpose: The purpose of this study is to develop a new systematic strategy for differential proteomic analysis. Experimental design: The new systematic strategy was developed by coupling the stable isotope-coded N-terminal acetyl labeling for guanidinated peptides with LTQ-FT MS for accurate data acquisition, and an in-house graphic user interface program called "MS-based acetyl quantification" for automatic data processing. Results: The standard peptide mixture test showed that this method is easy and highly effective, with a linear dynamic range from 0.1 to 10 (R2 value >0.999 and slope error <5%), down to 25 fmol. Moreover, the range of quantitative ratios differing from the target value of 1.0 was statistically determined to be (0.6527, 1.5350) for the 99% confidence level in a fraction of plasma samples. The practicability of this method was further demonstrated in a pilot study on the differential proteomic analysis of cerebrospinal fluid, with the uncovering of 33 dysregulated proteins from different development stages. Conclusions and clinical Relevance: The outcome of the differential proteomic analysis of plasma protein and cerebrospinal fluid confirmed the whole strategy as a promising alternative for exploration of potential biomarker in complex clinical or biological samples. © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Persistent Identifierhttp://hdl.handle.net/10722/342379
ISSN
2023 Impact Factor: 2.1
2023 SCImago Journal Rankings: 0.572
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, Xin-
dc.contributor.authorZhang, Jiyang-
dc.contributor.authorZheng, Zhaobin-
dc.contributor.authorYang, Xing-
dc.contributor.authorJia, Wei-
dc.contributor.authorLi, Lei-
dc.contributor.authorGong, Yan-
dc.contributor.authorCai, Yun-
dc.contributor.authorZhu, Yunping-
dc.contributor.authorHe, Fuchu-
dc.contributor.authorYing, Wantao-
dc.contributor.authorQian, Xiaohong-
dc.date.accessioned2024-04-17T07:03:24Z-
dc.date.available2024-04-17T07:03:24Z-
dc.date.issued2010-
dc.identifier.citationProteomics - Clinical Applications, 2010, v. 4, n. 6-7, p. 633-643-
dc.identifier.issn1862-8346-
dc.identifier.urihttp://hdl.handle.net/10722/342379-
dc.description.abstractPurpose: The purpose of this study is to develop a new systematic strategy for differential proteomic analysis. Experimental design: The new systematic strategy was developed by coupling the stable isotope-coded N-terminal acetyl labeling for guanidinated peptides with LTQ-FT MS for accurate data acquisition, and an in-house graphic user interface program called "MS-based acetyl quantification" for automatic data processing. Results: The standard peptide mixture test showed that this method is easy and highly effective, with a linear dynamic range from 0.1 to 10 (R2 value >0.999 and slope error <5%), down to 25 fmol. Moreover, the range of quantitative ratios differing from the target value of 1.0 was statistically determined to be (0.6527, 1.5350) for the 99% confidence level in a fraction of plasma samples. The practicability of this method was further demonstrated in a pilot study on the differential proteomic analysis of cerebrospinal fluid, with the uncovering of 33 dysregulated proteins from different development stages. Conclusions and clinical Relevance: The outcome of the differential proteomic analysis of plasma protein and cerebrospinal fluid confirmed the whole strategy as a promising alternative for exploration of potential biomarker in complex clinical or biological samples. © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.-
dc.languageeng-
dc.relation.ispartofProteomics - Clinical Applications-
dc.subjectCerebrospinal fluid-
dc.subjectGuanidination-
dc.subjectLTQ-FT MS-
dc.subjectMS-based acetyl quantification-
dc.subjectN-terminal acetyl labeling-
dc.titleA systematic N-terminal peptide quantitative labeling strategy for differential proteomic analysis-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/prca.200900065-
dc.identifier.pmid21137082-
dc.identifier.scopuseid_2-s2.0-77955812510-
dc.identifier.volume4-
dc.identifier.issue6-7-
dc.identifier.spage633-
dc.identifier.epage643-
dc.identifier.eissn1862-8354-
dc.identifier.isiWOS:000280434200008-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats